{
  "query": "give me comapny financial overview ",
  "timestamp": "2025-09-06 07:23:57",
  "config": {
    "top_k": 5,
    "similarity_threshold": 0.0,
    "reranking_enabled": true,
    "hybrid_search_enabled": true,
    "hybrid_search_weight": 0.7
  },
  "results": [
    {
      "id": 1,
      "text": "aire). The overall investment by all partners in NHa is \nover EUR 60 million, in equity and bond \nfinancing \n(guaranteed \nby \nthe \nNormandy \nRegion). IBAs contribution amounted to EUR 6 \nmillion in equity and EUR 1,5 million in \nconvertible Bond financing (see note 6.2.3). IBAs investment also includes the sale of \nintellectual property related to the Cyclone400 \ncyclotron to NHa. The gain on this transaction \namounted to EUR 5 million which was reduced \nby EUR 2 million (39.81%) for unrealized gain in \n2019. IBA has no capital commitments as at December \n31, 2022 and December 31, 2023 to participate \nin any potential future funding of Normandy \nHadrontherapy SAS.",
      "similarity_score": 0.7855030435577223,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 816,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 2,
      "text": "nd Share premium \n85 980 \n85 980 \nReserves and Retained earnings \n5.9. 29 971 \n20 232 \nEQUITY \n115 951 \n106 212 \nNon-current borrowings \n5.10. 10 647 \n7 114 \nNon-current lease liabilities \n5.10. 20 811 \n21 896 \nNon-current provisions \n5.11. 7 479 \n6 247 \nNon-current derivative financial liabilities \n7.3. 1 221 \n217 \nDeferred tax liabilities \n4.7.2. 756 \n286 \nOther non-current liabilities \n5.12. 5 862 \n2 955 \nNon-current liabilities \n46 776 \n38 715 \nCurrent borrowings \n5.10. 3 734 \n6 469 \nCurrent lease liabilities \n5.10. 5 675 \n6 104 \nCurrent provisions \n5.11 \n7 647 \n8 783 \nCurrent derivative f",
      "similarity_score": 0.7853390445649018,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 582,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 3,
      "text": "no capital commitments as at December \n31, 2022 and December 31, 2023 to participate \nin any potential future funding of Normandy \nHadrontherapy SAS. IBA has therefore not accounted for its share of \nthe loss and negative equity of Normandy \nHadrontherapy SAS beyond its value of the \ncapital invested. The following table illustrates the summarized financial information of the associates: (EUR 000) \nDecember 31, 2022 \nDecember 31, 2023 \nInvestment in affiliated companies \nCurrent assets \n31 942 \n28 364 \nNon-current assets \n89 035 \n88 949 \nCurrent liabilities (-) \n-14 505 \n-21 637 \nNon-Current l",
      "similarity_score": 0.7903080536212084,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 817,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 4,
      "text": "Cash and cash equivalents are detailed as follows: (EUR 000) \nDecember 31, 2022 \nDecember 31, 2023 \nBank balances and cash \n108 366 \n109 306 \nAccounts with restrictions shorter than 3 months \n0 \n0 \nShort-term bank deposits \n50 000 \n0 \nCASH AND CASH EQUIVALENTS \n158 366 \n109 306 \n5.9. EQUITY \nAs December 31, 2023, 49.11% of IBAs stock \nwas traded on Euronext. Full details of the \nGroups shareholders are set out in the section \nThe stock market and shareholders of this \nannual report. In 2023, the General Assembly \nhas approved a dividend of EUR 0.21 per share \nas recommended by IBAs Board of Directors, for \na total amount of EUR 6.1 million, which has \nbeen paid during the year.",
      "similarity_score": 0.7852835405715002,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 851,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 5,
      "text": "=== Page 187 ===\nIBA Rapport annuel 2023 \n184. authorisation to increase the capital granted to \nthe Board of Directors by the Extraordinary \nGeneral Meeting of 12 June 2013, at the price of \n 11.52 per share, i.e. at the accounting par of \n1.4035 corresponding to the accounting par \napplicable at the time of the issue of the warrants \nplus an issue premium of 10.1165, which \nresulted in a correlative increase in the capital of \n 89,122.25 from 42,413,196.29 to \n42,502,318.54 and the creation of 63,500 new \nshares. As of December 31, 2023, there were 1.110.231 \noutstanding stock options.",
      "similarity_score": 0.7885247730651045,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 1036,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    }
  ]
}